However, at the latest 2015 St Gallen International Breast Cancer Conference, the panel recommended Ki67-LI should be interpreted upon local laboratory values, and ER+/HER2− BCs could not be classified as two distinctive groups by IHC surrogate markers, as they belong to a spectrum of disease [9]. Here, ERBB2 is linked to breast carcinoma.